Henriksen Daniel Pilsgaard, Davidsen Jesper Rømhild, Laursen Christian B, Christiansen Anders, Damkier Per, Hallas Jesper, Pottegård Anton
Department of Respiratory Medicine, Odense University Hospital, B Winsløwsvej 19, 2, 5000, Odense C, Denmark.
Department of Clinical Biochemistry & Pharmacology, Odense University Hospital, Odense, Denmark.
Eur J Clin Pharmacol. 2017 Oct;73(10):1297-1304. doi: 10.1007/s00228-017-2286-3. Epub 2017 Jun 22.
Montelukast is a leukotriene receptor antagonist used in asthma and rhinitis treatment. Despite being marketed nearly two decades ago, little is known about its utilisation pattern.
Using the Danish National Prescription Registry, we identified subjects filling a montelukast prescription between 1998 and 2017. Using descriptive statistics, we reported the development in incidence, and prevalence, as well as a measure of treatment duration, and concomitant use of asthma- or anti-allergic therapy.
We identified 147,247 individuals filling 1,327,489 montelukast prescriptions. A total of 54,349 users (37%) filled only one montelukast prescription. The prevalence increased from 0.9/1000 persons in 1998 to 3.3/1000 persons in 2016. The rate of new users reached its maximum of 2.1/1000 person-years in 2009. Among new montelukast users, 28% were still users after 1 year. Among all montelukast initiators, 60% filled at least one prescription of short-acting beta-2-agonists (SABA) up to a year prior to montelukast initiation, and 49% filled a prescription of inhaled corticosteroids (ICS). Only 0.8% (n = 1148) of all individuals initiated montelukast without a redeemed prescription of short- or long-term inhalation therapy, systemic antihistamines, or nasal topical anti-allergic treatment.
The usage of montelukast has increased over threefold since its market entry in 1998, mainly driven by an increased number of prevalent users. The majority of individuals who initiated montelukast filled a prescription of SABA up to a year prior to montelukast initiation, whereas almost half filled a prescription of ICS.
孟鲁司特是一种用于治疗哮喘和鼻炎的白三烯受体拮抗剂。尽管该药于近二十年前上市，但对其使用模式却知之甚少。
利用丹麦国家处方登记系统，我们确定了在1998年至2017年间开具孟鲁司特处方的患者。通过描述性统计，我们报告了发病率、患病率的变化情况，以及治疗持续时间的衡量指标，还有哮喘或抗过敏治疗的联合使用情况。
我们确定了147,247名开具了1,327,489份孟鲁司特处方的患者。共有54,349名使用者（37%）仅开具了一份孟鲁司特处方。患病率从1998年的0.9/1000人增加到2016年的3.3/1000人。新使用者的比例在2009年达到最高，为2.1/1000人年。在新的孟鲁司特使用者中，28%在1年后仍在使用该药。在所有开始使用孟鲁司特的患者中，60%在开始使用孟鲁司特前一年至少开具过一份短效β2受体激动剂（SABA）处方，49%开具过吸入性糖皮质激素（ICS）处方。在所有患者中，只有0.8%（n = 1148）在未开具过短效或长效吸入治疗、全身性抗组胺药或鼻用局部抗过敏治疗处方的情况下就开始使用孟鲁司特。
自1998年上市以来，孟鲁司特的使用量增加了两倍多，主要是由于患病人数增加所致。大多数开始使用孟鲁司特的患者在开始使用该药前一年开具过SABA处方，而近一半患者开具过ICS处方。
